Dear colleagues and friends,
I am pleased to announce that NeuroNexus is once again an independent, private company! On January 1, 2019, we left the corporate umbrella of Nuvectra and were acquired by the NEL group, an investment company comprised of a small group of dedicated, private investors. Our entire organization is energized by this significant change – we’re calling it NeuroNexus “gen4.”
What does this mean for you? Going forward, our mission does not change. Our new independence translates to bringing more flexibility and focus to all aspects of our company, from sales and customer service to production and technical support. We are accelerating and expanding our research and engineering efforts to develop innovate neuroscience products and ground-breaking technologies for neural interfacing. Additionally, we are (re-)opened for grant and contract collaborations! Overall, we are even better positioned to work with you to find meaningful, cost-effective solutions for your research or product development programs.
NeuroNexus “gen4” remains dedicated to working at the forefronts of neuroscience, neurotechnology, and neuromodulation.
I look forward to interfacing with you in the future. Please feel free to contact me at email@example.com.
With warm regards,
Daryl R. Kipke, PhD
CEO and Director, NeuroNexus Technologies, Inc.
CEO and Director, NEL Group, Inc.